Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Sleep expert Dr. Abhay Sharma talks about how Zepbound is now approved by the FDA for the treatment of moderate to severe ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on January 13.Stay Ahead of the ...

An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...